Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This study is designed as a randomized, prospective study to test the efficacy of imiquimod
plus tazarotene in the treatment of LM. Eligible and consented patients will be randomized to
one of two treatment groups: 1) topical imiquimod group, or 2) topical imiquimod combined
with topical tazarotene group. All patients will undergo a staged surgical excision with rush
permanent sections to confirm negative histologic margins. This will be followed by a
surgical repair of the defect and long-term follow-up of five years to rule out recurrences.
Both groups will have a polygonal excision using 2mm margins per stage.